ReviewWorld journal of urology2013
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer.
Review in World journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer.Translational andrology and urology · 2020Review
- Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy.Prostate cancer · 2016Article
- Salvage local therapy for radiation-recurrent prostate cancer - where are we?Central European journal of urology · 2016Review
- Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.European urology · 2015Article
- Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Up to one-third of men can fail radical external beam radiotherapy for primary prostate cancer. Most of these men have expectant management with delayed hormones. However, around half of these men have localised recurrence. Challenges remain in identifying such men accurately, in order to enable them to undergo local salvage therapy which is potentially curative. Currently, this includes radical prostatectomy, brachytherapy and ablative whole-gland therapies, such as cryotherapy and high intensity focused ultrasound, all of which can carry significant morbidity. New approaches may involve targeting the area of recurrence alone--focal salvage therapy--in order to reduce tissue damage and thus reduce morbidity. This requires accurate localisation of intraprostatic recurrent disease and precision targeted ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.